About: Placental transfer and safety in pregnancy of medications under investigation to treat COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Placental transfer and safety in pregnancy of medications under investigation to treat COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Placental transfer and safety in pregnancy of medications under investigation to treat COVID-19
Creator	Mandelbrot, Laurent Peytavin, Gilles Picone, Olivier Sibiude, Jeanne Louchet, Margaux Tré-Luyer, Jean-Marc Tréluyer, Jean-Marc
topic	covid:6781845d9c6d05c033a2a29380fa0a28952ba7e2#this
Source	Elsevier; Medline; PMC; WHO
abstract	Abstract Background Treatment of COVID-19 is mostly symptomatic, but a wide range of medications are under investigation against SARS-CoV-2. Although pregnant women are excluded from clinical trials, they will inevitably receive therapies whenever they appear effective in non-pregnant patients and even under compassionate use. Method We conducted a review of the literature on placental transfer and pregnancy safety data of drugs under current investigation for COVID-19. Results Regarding remdesivir, there are no data in pregnant women. Several other candidates already have safety data in pregnant women, since they are repurposed drugs already used for their established indications. They may thus be used in pregnancy, although their safety in the context of COVID-19 may differ from conventional use. These include the HIV protease inhibitors such as lopinavir/ritonavir which have low placental transfer; interferon which does not cross the placental barrier, and (hydroxy) chloroquine, which have high placental transfer. There are also pregnancy safety and placental transfer data for colchicine, steroids, oseltamivir and azithromycin, as well as some monoclonals. However, some drugs are strictly prohibited in pregnancy due to known teratogenicity (thalidomide) or fetal toxicities (renin-angiotensin system blockers). Other candidates including tocilizumab and other IL-6 inhibitors, umifenovir and favipiravir have insufficient data on pregnancy outcomes. Conclusion In life-threatening cases of COVID-19, the potential risks of therapy to the fetus may be more than offset by the benefit of curing the mother. While preclinical and placental transfer studies are required for a number of potential anti-SARS CoV2 drugs, several medications can already be used in pregnant women.
has issue date	2020-06-22(xsd:dateTime)
bibo:doi	10.1016/j.ajogmf.2020.100159
bibo:pmid	32838264
has license	els-covid
sha1sum (hex)	6781845d9c6d05c033a2a29380fa0a28952ba7e2
schema:url	https://doi.org/10.1016/j.ajogmf.2020.100159
resource representing a document's title	Placental transfer and safety in pregnancy of medications under investigation to treat COVID-19
has PubMed Central identifier	PMC7308040
has PubMed identifier	32838264
schema:publication	Am J Obstet Gynecol MFM
resource representing a document's body	covid:6781845d9c6d05c033a2a29380fa0a28952ba7e2#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/6781845d9c6d05c033a2a29380fa0a28952ba7e2
is schema:about of	named entity 'Placental' named entity 'safety' named entity 'pregnancy' named entity 'Placental' named entity 'preterm births' named entity 'clinical trial' named entity 'Pregnant women' named entity 'psoriasis' named entity 'HIV' named entity 'ritonavir' named entity 'nucleoside reverse transcriptase inhibitors' named entity 'premature babies' named entity 'randomized clinical trials' named entity 'ritonavir' named entity 'liver' named entity 'virus replication' named entity 'adverse effects' named entity 'cell membrane' named entity 'Physiological' named entity 'influenza viruses' named entity 'pregnant women' named entity 'enzyme' named entity 'antidiabetic medication' named entity 'growth Restriction' named entity 'antiviral drug' named entity 'thalidomide' named entity 'nelfinavir' named entity 'teratomas' named entity 'phase III trial' named entity 'neuraminidase inhibitor' named entity 'lopinavir/ritonavir' named entity 'Baricitinib' named entity 'covid-19' named entity 'subcutaneous' named entity 'pregnancy' named entity 'drug toxicities' named entity 'leflunomide' named entity 'pregnancy' named entity 'NCT' named entity 'antihelminthic drug' named entity 'observational studies' named entity 'rheumatoid arthritis' named entity 'Sildenafil' named entity 'randomized controlled' named entity 'congenital malformation' named entity 'placental barrier' named entity 'excretion' named entity 'vertical transmission' named entity 'Retrospective study' named entity 'Arbidol' named entity 'JAK1' named entity 'Lopinavir' named entity 'pregnant women' named entity 'pregnant women' named entity 'renal failure' named entity 'antiviral' named entity 'renin' named entity 'randomized clinical' named entity '1, 2' named entity 'colchicine' named entity 'infliximab' named entity 'retinopathy' named entity 'plasma' named entity 'Pregnancy' named entity 'pregnancy' named entity 'Sildenafil' named entity 'COVID-19' named entity 'tolerability' named entity 'pregnancy' named entity 'sphingosine-1-phosphate receptor' named entity 'digestive disorders' named entity 'perfusion' named entity 'efflux'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software